Oxycodone Depot Teva

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxycodone Depot Teva (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodone Depot Teva, is an opioid analgesic presented as a depot formulation for systemic use. It is indicated for the management of moderate to severe chronic pain in adult patients when around‑the‑clock treatment is required. GNH India supplies Oxycodone Depot Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Oxycodone Depot Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Teva B.V

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Depot Teva is an opioid analgesic used in the management of pain pathways that involve central nociceptive processing.

Chronic cancer pain: provides long‑acting relief for patients with persistent tumor‑related pain.
Post‑surgical pain: maintains analgesia during the postoperative recovery period when oral dosing is not feasible.
Severe non‑cancer chronic pain: offers continuous opioid coverage for conditions such as severe osteoarthritis or neuropathic pain unresponsive to other therapies.

How It Works

Oxycodone binds primarily to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and diminish the perception of pain. This receptor interaction also decreases the release of neurotransmitters such as substance P and glutamate, contributing to its analgesic effect.

Side Effects

Oxycodone Depot Teva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Constipation: reduced gastrointestinal motility leading to hard stools.
Nausea: sensation of queasiness, sometimes progressing to vomiting.
Drowsiness: mild sedation or feeling of fatigue.
Dry mouth: decreased salivary flow causing oral discomfort.
Dizziness: light‑headed sensation, especially when standing quickly.
Pruritus: mild itching without rash.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure causing faintness.
Opioid use disorder: dependence or addiction with misuse potential.
Adrenal insufficiency: impaired cortisol production leading to fatigue and weakness.
Severe allergic reaction: anaphylaxis with rash, swelling, and airway compromise.
QT interval prolongation: cardiac rhythm disturbance detectable on ECG.

Precautions & Warnings

When prescribing Oxycodone Depot Teva, clinicians should consider several safety measures to minimize risk.

Assess pain severity and opioid tolerance: ensure the patient requires long‑acting opioid therapy.
Evaluate respiratory function: monitor for signs of depression, especially in opioid‑naïve individuals.
Review concomitant medications: avoid combining with other central nervous system depressants.
Counsel on dependence risk: discuss safe use, storage, and disposal.
Monitor for endocrine effects: watch for signs of adrenal insufficiency or hormonal changes.
Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone Depot Teva can interact with a variety of medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined use markedly increases risk of respiratory depression and profound sedation.
CNS depressants: concurrent administration with alcohol, barbiturates or other sedatives can cause life‑threatening respiratory compromise.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise oxy‑dosed plasma levels, heightening toxicity risk.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can reduce conversion to active metabolites, affecting analgesia.
Anticholinergics: may exacerbate constipation and urinary retention.
Diuretics: can increase risk of orthostatic hypotension when combined with opioid‑induced vasodilation.

Frequently Asked Questions

Oxycodone Depot Teva is a long‑acting opioid formulation indicated for the management of moderate to severe chronic pain, including cancer‑related pain and severe non‑cancer pain, when continuous around‑the‑clock analgesia is required.

Oxycodone hydrochloride binds to μ‑opioid receptors in the central nervous system, activating inhibitory pathways that lower neuronal excitability and reduce the release of pain‑transmitting neurotransmitters, thereby diminishing the perception of pain.

The dosage of Oxycodone Depot Teva is individualized by the prescribing clinician based on the patient’s pain severity, opioid tolerance, and clinical response. No fixed regimen is provided here.

Opioid use during pregnancy and lactation carries risks, including neonatal respiratory depression and potential for dependence. Use only if the potential benefit justifies the risk, and consult a specialist obstetrician or neonatologist.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with immediate‑release oxycodone tablets, the depot formulation provides sustained plasma concentrations, reducing dosing frequency and improving adherence for patients needing continuous analgesia, while sharing a similar safety and side‑effect profile.

Store the product at or below 25 °C in its original packaging, protecting it from moisture, heat and direct sunlight. Keep it out of reach of children and unauthorized personnel.

The depot formulation is administered by a healthcare professional via the approved route (typically subcutaneous or intramuscular injection) according to the prescribing information, ensuring proper technique and aseptic conditions.

The most serious risks include respiratory depression, severe hypotension, opioid use disorder, and rare but life‑threatening allergic reactions such as anaphylaxis. Immediate medical attention is required if these occur.

Patients with known hypersensitivity to oxycodone or any formulation components, those with severe respiratory insufficiency, acute or severe asthma, or untreated obstructive sleep apnea should avoid this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.